𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Is viloxazine an antidepressant? A placebo-controlled double-blind study in major depressive disorder presenting in a general hospital

✍ Scribed by C. Thompson; G. Isaacs

Publisher
John Wiley and Sons
Year
1991
Tongue
English
Volume
6
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Viloxazine was one of the first of the ‘second‐generation’ antidepressants. Its relative lack of cardiotoxic, anticholinergic, sedative and seizure‐inducing adverse effects suggested its use as an antidepressant in general hospitals where tricyclic antidepressants might be frequently contraindicated. We conducted a double‐blind trial of 300 mg viloxazine against placebo in 43 patients with major depressive disorder. The placebo‐treated group showed a slightly, but not significantly, greater improvement in depression scores using observer and self‐rating scales over those using viloxazine. A review of previous placebo‐controlled studies of viloxazine offers little support to its use as an antidepressant.

📜 SIMILAR VOLUMES

A double blind, placebo-controlled pilot
A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression
✍ Paul E. Holtzheimer III; Thomas W. Meeks; Mary E. Kelley; Mustafa Mufti; Raymond 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

## Abstract ## Objective Depression in older adults is often associated with cognitive abnormalities and may predict later development of a primary cognitive disorder. This double‐blind, randomized, placebo‐controlled pilot study was designed to assess the safety and efficacy of galantamine augmen

A randomised, double-blind, placebo-cont
A randomised, double-blind, placebo-controlled, 5-weeks' study of org 3770 (mirtazapine) in major depression
✍ M. C. Khan 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 433 KB

Fifty-four hospitalised and outpatients with a DSM 111 diagnosis of major depressive disorder and 21-item HPRSD score of 2 18, were randomised to 5 weeks' of treatment with either Org 3770 (n=27; 20-60mg/day) or placebo (n = 27). The treatment with Org 3770 resulted in statistically significant and

Celecoxib as an adjunct in the treatment
Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study
✍ Fabiano G. Nery; Emel S. Monkul; John P. Hatch; Manoela Fonseca; Giovana B. Zunt 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

## Abstract ## Objective To investigate whether the cox‐2 inhibitor celecoxib has antidepressant effects in bipolar disorder (BD) patients during depressive or mixed phases. ## Methods We studied 28 DSM‐IV BD patients who were experiencing a depressive or mixed episode and were on a stable dose

St. John's wort and Kava in treating maj
St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial
✍ Jerome Sarris; David J. Kavanagh; Gary Deed; Kerry M. Bone 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

## Abstract ## Objective We report the first randomised controlled trial (RCT) using a combination of St. John's wort (SJW) and Kava for the treatment of major depressive disorder (MDD) with comorbid anxiety. ## Methods Twenty‐eight adults with MDD and co‐occurring anxiety were recruited for a d

Randomized double-blind placebo-controll
Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study
✍ Gregory H. Pelton; Oliver L. Harper; Matthias H. Tabert; Harold A. Sackeim; Niko 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

## Abstract ## Objective To assess combined antidepressant and cognitive enhancer treatment in elderly patients presenting with depression plus cognitive impairment. ## Methods Twenty‐three elderly (>50 years old) depressed, cognitively impaired (DEP‐CI) patients participated in a pilot study. W

Add-on mirtazapine improves depressive s
Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase
✍ Viacheslav Terevnikov; Jan-Henry Stenberg; Jari Tiihonen; Marina Joffe; Mark Bur 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB

Depression is common in schizophrenia and worsens its course. The role of antidepressants for schizophrenic depression remains unclear. In this study, the efficacy of add-on mirtazapine on depression in schizophrenia was explored in a subsidiary arm of a recent randomized controlled trial. Patients